HomeCompareTRKYY vs ABBV

TRKYY vs ABBV: Dividend Comparison 2026

TRKYY yields 6.77% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRKYY wins by $36318.42M in total portfolio value
10 years
TRKYY
TRKYY
● Live price
6.77%
Share price
$1.80
Annual div
$0.12
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36318.52M
Annual income
$35,315,909,402.35
Full TRKYY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TRKYY vs ABBV

📍 TRKYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRKYYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRKYY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRKYY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRKYY
Annual income on $10K today (after 15% tax)
$575.17/yr
After 10yr DRIP, annual income (after tax)
$30,018,522,992.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TRKYY beats the other by $30,018,501,935.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRKYY + ABBV for your $10,000?

TRKYY: 50%ABBV: 50%
100% ABBV50/50100% TRKYY
Portfolio after 10yr
$18159.31M
Annual income
$17,657,967,087.06/yr
Blended yield
97.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TRKYY
No analyst data
Altman Z
0.5
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRKYY buys
0
ABBV buys
0
No recent congressional trades found for TRKYY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRKYYABBV
Forward yield6.77%3.06%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$36318.52M$102.3K
Annual income after 10y$35,315,909,402.35$24,771.77
Total dividends collected$36249.52M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRKYY vs ABBV ($10,000, DRIP)

YearTRKYY PortfolioTRKYY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,053$1,353.33$11,550$430.00+$503.00TRKYY
2$15,946$3,049.01$13,472$627.96+$2.5KTRKYY
3$24,602$7,539.65$15,906$926.08+$8.7KTRKYY
4$48,067$21,742.67$19,071$1,382.55+$29.0KTRKYY
5$130,834$79,402.54$23,302$2,095.81+$107.5KTRKYY
6$543,969$403,976.72$29,150$3,237.93+$514.8KTRKYY
7$3,721,516$3,139,469.58$37,536$5,121.41+$3.68MTRKYY
8$44,128,574$40,146,551.76$50,079$8,338.38+$44.08MTRKYY
9$937,021,710$889,804,135.69$69,753$14,065.80+$936.95MTRKYY
10$36,318,522,632$35,315,909,402.35$102,337$24,771.77+$36318.42MTRKYY

TRKYY vs ABBV: Complete Analysis 2026

TRKYYStock

Türkiye Sinai Kalkinma Bankasi A.S. operates as a development and investment bank in Turkey and internationally. The company engages in the industrial investments, energy and resource efficiency, environmental investments, renewable energy, sustainable tourism, women's employment and equal opportunity, occupational health and safety, investments in developing regions, education and health investments, R&D and innovation, and working capital financing activities. It also provides project finance for energy generation and power plants; electricity distribution and natural gas distribution projects; mergers and acquisitions; logistics, transportation, and telecommunications; and public - private partnership projects. In addition, the company offers wholesale banking and SME financing, foreign trade finance, working capital financing, and machinery and equipment leasing services; letter of guarantees/external guarantees/letter of credits; and export/Eximbank endorsement, and country loans. Further, it provides corporate finance products and services, such as public offering preparation and brokerage, debt instrument issues, and mergers and acquisitions advisory; derivatives products, such as forwards, options, caps and floors, swaps, and swaptions; repo, warrant, and foreign derivative transactions; securities loans; brokerage for stock and bonds trading; and portfolio management and investment advisory services. Additionally, the company offers financial planning strategy, feasibility, valuation, and restructuring services, as well as sectoral analysis studies; and engineering and technical advisory, real estate appraisal, economic research, and sustainability consultancy services. Türkiye Sinai Kalkinma Bankasi A.S. was incorporated in 1950 and is headquartered in Istanbul, Turkey.

Full TRKYY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TRKYY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRKYY vs SCHDTRKYY vs JEPITRKYY vs OTRKYY vs KOTRKYY vs MAINTRKYY vs JNJTRKYY vs MRKTRKYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.